Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Minimal change nephrotic syndrome (MCNS) accounts for more than 20% of primary nephrotic syndrome cases diagnosed by kidney biopsy in elderly individuals aged 70 years and older in Japan. However, its clinical characteristics in this age group remain unclear. This study aimed to clarify the clinical features of MCNS in elderly patients by stratifying cases based on age (younger than 70 years vs. 70 years and older) and comparing clinical backgrounds, duration to achieve complete remission, and early relapse rates between the two groups.
We retrospectively reviewed cases of patients aged 18 years or older who were pathologically diagnosed with MCNS by kidney biopsy at our institution between April 1, 2008 and March 31, 2023. Patients were divided into two groups: Group Y (18–69 years) and Group E (70 years and older). We compared clinical data at disease onset, clinical backgrounds, treatment response, and early relapse rates between the groups. Cases that did not achieve complete remission within 3 months after initiation of therapy were excluded, considering the possibility of other underlying diseases. The follow-up period was set from April 1, 2008 to March 31, 2025.
A total of 36 patients were pathologically diagnosed with MCNS by kidney biopsy. Of these, 29 patients who achieved complete remission within 3 months after treatment initiation were included in the analysis. Group Y consisted of 21 patients (mean age at diagnosis: 40.2 ± 17.7 years), and group E consisted of 8 patients (mean age: 73.1 ± 2.7 years). The overall mean follow-up period was 3,686.2 ± 1,663.4 days.
There were no significant differences between the two groups in the prevalence of hypertension, dyslipidemia, diabetes mellitus, or smoking history. Similarly, there were no significant differences in eGFR, serum albumin levels, or selectivity index at admission. However, urinary protein excretion was higher in group E (group Y: 7.56 g/gCr [IQR 5.38–11.74]; group E: 12.97 g/gCr [IQR 8.54–17.59]).
Spontaneous remission occurred in one patient in group Y but in none in group E. The proportion of patients receiving methylprednisolone pulse therapy and the mean initial prednisolone dose (group Y: 0.69 mg/kg; group E: 0.73 mg/kg) did not differ significantly between the two groups.
The median time to complete remission after steroid initiation was 16.0 days [IQR 11–25] in group Y and 22 days [IQR 18–71] in group E. Although the difference was not statistically significant, the duration tended to be longer in the elderly group. Relapse within one year after complete remission occurred in three patients (14.3%) in group Y and three patients (37.5%) in group E, with no significant difference. The incidence of infections and thrombotic events during initial therapy was also comparable between groups.
Elderly patients presented with higher levels of proteinuria at onset and it was suggested that they may require a longer duration to achieve complete remission.
